Want to see TSE:HEM full AI Analyst Report?
HEM Stock Chart & Stats
C$0.08
C$0.03(23.81%)
At close: 4:00 PM EST
C$0.08
C$0.03(23.81%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.16
Previous CloseN/A
Volume356.00K
Average Volume (3M)138.35K
Market Cap
C$10.48M
Enterprise ValueC$14.32M
Total Cash (Recent Filing)C$319.24K
Total Debt (Recent Filing)C$3.62M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Autologous Cell-therapy PlatformHemostemix’s core business is a platform of autologous, blood-derived stem/progenitor cell therapies. Platform approaches can drive durable advantages by enabling multiple indication expansion, reuse of development knowledge, and differentiated safety profiles tied to patient-derived material.
Focus On Regenerative Medicine For Ischemic DiseaseTargeting ischemic and cardiovascular conditions aligns the company with structural healthcare demand and unmet needs; durable tailwinds from aging populations and limited existing curative options can sustain long-term market opportunities if clinical efficacy is demonstrated.
Measured Debt Growth In Latest PeriodBalance-sheet commentary notes debt (~$3.6M) did not increase sharply in the latest period, implying management has shown restraint in levering the company further. That discipline can preserve financing optionality and modestly reduce near-term refinancing pressure versus rapidly rising debt.
Bears Say
No Revenue And Negative Gross ProfitThe company reports no commercialization and has sustained operating and net losses that worsened recently. Without product revenue, business viability depends on successful clinical outcomes or continual funding, making long-term sustainability contingent on high-risk development milestones.
Negative Shareholders' Equity And Shrinking Asset BaseConsistently negative equity and a declining asset base materially limit financial flexibility, increasing reliance on dilutive capital raises. This structural weakness constrains the company’s ability to absorb shocks, invest in trials, or negotiate favorable financing terms over the medium term.
Persistent Negative Cash Flow And Rising Cash BurnOngoing negative operating and free cash flows with accelerating cash burn create a durable funding requirement. Repeated external financing risks dilution and could interrupt development timelines if capital access tightens, making execution dependent on continual capital markets access.
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.04 and its highest was C$0.16 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$10.48M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Aug 31, 2026 which is in 60 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 197,796,450 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Technical Analysis
Options Prices
Currently, No data available
---